BACKGROUND The present review summarizes the cellular action of TGF‐β in benign and malignant growth of the prostate. METHODS. TGF‐β is a pleiotropic growth factor. It plays an important role in the regulation of growth and differentiation in many cells. In benign prostatic epithelia, its action is mediated through a paracrine mechanism. It inhibits proliferation and induces apoptosis in prostatic epithelia. It provides a mechanism to maintain epithelial homeostasis in the prostate. In prostatic stroma, its continual action leads to smooth muscle differentiation. This effect of TGF‐β may regulate the development of prostatic smooth muscle nodules in benign prostatic hyperplasia. RESULTS As prostatic epithelial cells undergo malignant transformation, two major events occur regarding TGF‐β action. These include the loss of expression of functional TGF‐β receptors and overproduction of TGF‐β in malignant cells. The loss of expression of functional TGF‐β receptors provides a growth advantage to cancer cells over their benign counterparts. The overproduction of TGF‐β by cancer cells has a multitude of adverse consequences. TGF‐β can promote extracellular matrix production, induce angiogenesis, and inhibit host immune function. The biological consequence of these activities is an enhanced tumorigenicity in prostate cancer. Results of our recent studies with a rat prostate cancer model suggest that the immunosuppressive effect of TGF‐β seems to be the primary cause of tumor progression. This is because, if these cancer cells were engineered to reduce the production of TGF‐β, tumor growth was inhibited in syngeneic hosts but not in immune compromised hosts. CONCLUSIONS Our future research should take advantage of this knowledge to devise therapeutic strategies aimed at eradicating prostate cancer. Prostate 39:285–290, 1999. © 1999 Wiley‐Liss, Inc.
BACKGROUND SGP‐2 is a ubiquitous secreted glycoprotein that prevents cellular apoptosis. This study was carried out to determine the extracellular action of SGP‐2 in a model of tumor necrosis factor‐α (TNF)‐induced cytotoxicity using two human prostatic cancer lines, LNCaP and PC3. These two lines were selected because LNCaP cells are highly sensitive to the cytotoxic effect of TNF, while PC3 cells are resistant to TNF at 24 hr. METHODS Cells were cultured in the presence or absence of TNF (10 ng/ml). LNCaP cells were treated with varying concentrations of exogenous SGP‐2, while PC3 cells were treated with antisera to SGP‐2 with and without exogenous SGP‐2. Following a 24‐hr treatment, cultures were assessed by counting of cell number and by the trypan blue exclusion assay. RESULTS Western blot analysis of conditioned media revealed that PC3 secreted more SGP‐2 than did LNCaP. The sensitivity to TNF in LNCaP cells was reduced by the addition of exogenous SGP‐2. PC3 cells became sensitive to TNF when SGP‐2 antibody was added to the culture. The effect of SGP‐2 antibody on PC3 cells was reversed by the addition of exogenous SGP‐2 to the culture. CONCLUSIONS These results suggest that SGP‐2 can act as an extracellular mediator of anti‐TNF‐induced cytotoxicity. Prostate 39:87–93, 1999. © 1999 Wiley‐Liss, Inc.
BACKGROUND LNCaP cells are androgen‐sensitive human prostate cancer cells. They are characterized by a bell‐shaped growth curve in response to increasing doses of dihydrotestosterone (DHT) in culture. At a low concentration of DHT (0.1 nM), these cells show an increase in proliferation, but their growth is arrested at a high concentration (100 nM) of DHT. Results of our previous study demonstrated that the inhibitory effect of DHT at a high concentration was mediated through the action of TGF‐β1. The objective of the present study was to elucidate the mechanism of the proliferative effect of DHT in LNCaP cells. METHODS AND RESULTS DHT stimulated LNCaP proliferation only when cells were cultured in the presence of serum. In serum‐free cultures, the characteristic DHT‐induced proliferation was not observed. The addition of neutralizing antibody against FGF‐2 (basic fibroblast growth factor) was able to inhibit this DHT‐induced proliferation. These results suggest that the proliferative effect of DHT was mediated through the action of FGF‐2. However, results of the reverse transcriptase polymerase chain reaction indicated that LNCaP cells did not express FGF‐2 message. As a result, the source of FGF‐2 in these cultures must be the serum supplemented in the culture media. FGF‐2 can bind to heparin sulfate chains within the extracellular matrix (ECM). In cultures treated with exogenous heparin, the proliferative effect of DHT was abolished. These results led to the development of the hypothesis that DHT treatment mediates the release of FGF‐2 entrapped in the ECM through increased heparinase activity. The addition of heparinase to cultures of LNCaP cells, in the absence of DHT, was able to stimulate cell proliferation. Moreover, 0.1 nM DHT caused a significant increase in heparinase activity. CONCLUSIONS These results provide a possible mechanism for DHT action in LNCaP cells. In the absence of DHT, FGF‐2 in culture was trapped in the extracellular matrix and was not available to interact with LNCaP cells. However, in the presence of 0.1 nM DHT, heparinase activity in the culture was elevated and, as a result, it liberated the trapped FGF‐2 which, in turn, stimulated proliferation in LNCaP cells. Prostate 44:124–132, 2000. © 2000 Wiley‐Liss, Inc.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.